B. Braun Melsungen AG is a medical technology company with a specific and high-stakes attack surface. Founded in 1839 and now generating approximately €9.4 billion in annual sales, it operates globally with over 64,000 employees. The threat model here is physical-digital convergence: the company manufactures devices that directly interface with patients, from the Braunüle infusion device to dialysis machines and the surgical instruments of its Aesculap division. Securing these systems means protecting the integrity of medical devices, the confidentiality of patient data flowing through clinical workflows, and the availability of pharmaceutical production lines.
The technical domains map directly to cybersecurity challenges: medical technology firmware and connected device security, industrial control systems in pharmaceutical manufacturing, and the integrity of supply chain software for products like Lipofundin clinical nutrition solutions. A security team here is dealing with OT/IT convergence in factories, protecting proprietary R&D data for surgical innovations, and ensuring regulatory compliance across every continent of operation. The work is not theoretical; vulnerabilities in infusion pumps or production systems have direct, tangible consequences.
With six generations of family stewardship, the company's long-term perspective likely extends to its security investments. This isn't a startup sprinting toward an exit; it's an institution where the continuity of operations and the safety of its products are existential concerns. The security posture must be built to match that permanence, addressing threats from ransomware targeting production uptime to sophisticated espionage aimed at intellectual property in medical device design.
